JP2016513075A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513075A5
JP2016513075A5 JP2015552798A JP2015552798A JP2016513075A5 JP 2016513075 A5 JP2016513075 A5 JP 2016513075A5 JP 2015552798 A JP2015552798 A JP 2015552798A JP 2015552798 A JP2015552798 A JP 2015552798A JP 2016513075 A5 JP2016513075 A5 JP 2016513075A5
Authority
JP
Japan
Prior art keywords
composition
composition according
individual
nucleoside
nucleoside transporter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015552798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513075A (ja
Filing date
Publication date
Priority claimed from US13/794,486 external-priority patent/US20140199404A1/en
Application filed filed Critical
Publication of JP2016513075A publication Critical patent/JP2016513075A/ja
Publication of JP2016513075A5 publication Critical patent/JP2016513075A5/ja
Pending legal-status Critical Current

Links

JP2015552798A 2013-01-11 2014-01-10 ヌクレオシド輸送体のレベルに基づくがんの処置方法 Pending JP2016513075A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361848780P 2013-01-11 2013-01-11
US61/848,780 2013-01-11
US201361752397P 2013-01-14 2013-01-14
US61/752,397 2013-01-14
US13/794,486 2013-03-11
US13/794,486 US20140199404A1 (en) 2013-01-11 2013-03-11 Method for treating cancer based on level of a nucleoside transporter
PCT/US2014/011006 WO2014110345A1 (en) 2013-01-11 2014-01-10 Method for treating cancer based on level of a nucleoside transporter

Publications (2)

Publication Number Publication Date
JP2016513075A JP2016513075A (ja) 2016-05-12
JP2016513075A5 true JP2016513075A5 (enExample) 2017-02-16

Family

ID=51165318

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552798A Pending JP2016513075A (ja) 2013-01-11 2014-01-10 ヌクレオシド輸送体のレベルに基づくがんの処置方法

Country Status (7)

Country Link
US (1) US20140199404A1 (enExample)
EP (1) EP2943191A4 (enExample)
JP (1) JP2016513075A (enExample)
CA (1) CA2897673A1 (enExample)
HK (1) HK1217180A1 (enExample)
MX (1) MX2015008888A (enExample)
WO (1) WO2014110345A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
SI3248600T1 (sl) 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
PL1931321T3 (pl) 2005-08-31 2019-08-30 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
WO2008150532A1 (en) * 2007-06-01 2008-12-11 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
MX378130B (es) 2009-04-15 2025-03-10 Abraxis Bioscience Llc Métodos y composiciones de nanopartículas sin priones.
PT2552438T (pt) 2010-03-26 2016-07-07 Abraxis Bioscience Llc Métodos de tratamento de carcinoma hepatocelular
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
AU2012249371B2 (en) 2011-04-28 2017-06-08 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US10744110B2 (en) 2013-03-12 2020-08-18 Abraxis Bioscience, Llc Methods of treating lung cancer
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
KR102606071B1 (ko) 2015-06-29 2023-11-27 아브락시스 바이오사이언스, 엘엘씨 상피양 세포 종양을 치료하는 방법
WO2017095632A1 (en) * 2015-11-30 2017-06-08 Mayo Foundation For Medical Education And Research Heatr1 as a marker for chemoresistance
AU2017340913A1 (en) * 2016-10-07 2019-04-18 Abraxis Bioscience, Llc Methods of treating biliary tract cancer
US11306111B2 (en) 2017-07-31 2022-04-19 January Therapeutics, Inc. Organophosphate derivatives
KR102837015B1 (ko) 2018-03-20 2025-07-23 아브락시스 바이오사이언스, 엘엘씨 mTOR 억제제 및 알부민의 나노입자의 투여를 통한 중추 신경계 장애의 치료 방법
US11708637B2 (en) 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
CA3158764A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200204907B (en) * 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.
SI3248600T1 (sl) * 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
AU2011232862B2 (en) * 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
JP2013523712A (ja) * 2010-03-30 2013-06-17 クラヴィス・ファルマ・アーエスアー ゲムシタビン−5’−エライデートを用いて癌を治療又は緩和するための方法及び組成物
ES2639038T3 (es) * 2010-06-02 2017-10-25 Abraxis Bioscience, Llc Métodos para el tratamiento de cáncer de vejiga
EP2739290A4 (en) * 2011-08-02 2015-04-15 Clovis Oncology Inc METHOD FOR SELECTION OF CHEMOTHERAPEUTICS AGAINST ADENOCARCINOMAS

Similar Documents

Publication Publication Date Title
JP2016513075A5 (enExample)
JP2016513097A5 (enExample)
JP2016512513A5 (enExample)
JP2016504362A5 (enExample)
JP2017534638A5 (enExample)
JP2010529025A5 (enExample)
CY1125152T1 (el) Συνθεσεις και μεθοδοι για τη μειωση της νεοαγγειωσης του οφθαλμου
HK1217180A1 (zh) 根據一種核苷轉運載體的水平治療癌症的方法
JP2016512506A5 (enExample)
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
JP2018111728A5 (enExample)
JP2019529350A5 (enExample)
SG10201906075VA (en) Methods of treating cancer
JP2016041733A5 (enExample)
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
JP2018508593A5 (enExample)
JP2013518815A5 (enExample)
JP2016539125A5 (enExample)
MX388251B (es) Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
JP2018529666A5 (enExample)
HK1259083A1 (zh) 用於治疗系统性肥大细胞增多症的方法和组合物
JP2019529520A5 (enExample)
JP2019501920A5 (enExample)
JP2019528285A5 (enExample)
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases